Phase 3: Study: Seizure Incidence Study

Protocol	Blind	Design	Centers	Length	Dosing	Setting	Diagnosis	Levels	Bupropion (po)	N*
208	None	Fixed Dose	109	8 weeks and ongoing	Fixed	Inpatient and Outpatient	Depression	1	150 mg am 150 mg pm	3100

*Number of patients studied, with the exception of 67 patients excluded from all analyses except premature discontinuation because they never received or it is unknown if they received study medication.

 

 

 

 

 

Bupropion Sustained-Release Clinical Review                               47

 

 

 

Back a Page
Next Page
Back to Wellbutrin SR® NDA Index Page
Back to Main Index